145 related articles for article (PubMed ID: 12214161)
1. Low-dosage intravenous immunoglobulin in the management of a patient with acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance.
Hayashi T; Yagi H; Suzuki H; Nonaka Y; Nomura T; Sakurai Y; Shibata M; Matsumoto M; Yamamoto Y; Fujimura Y
Pathophysiol Haemost Thromb; 2002; 32(1):33-9. PubMed ID: 12214161
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of inhibitors in acquired von Willebrand syndrome.
Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T
Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997
[TBL] [Abstract][Full Text] [Related]
3. Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein.
He S; Cao H; Magnusson CG; Eriksson-Berg M; Mehrkash M; Schenck-Gustafsson K; Blombäck M
Thromb Res; 2001 Aug; 103(3):241-8. PubMed ID: 11672586
[TBL] [Abstract][Full Text] [Related]
4. Acquired von Willebrand syndrome: diagnostic problems and therapeutic options.
Eikenboom JC; Tjernberg P; Van Marion V; Heering KJ
Am J Hematol; 2007 Jan; 82(1):55-8. PubMed ID: 16986130
[TBL] [Abstract][Full Text] [Related]
5. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin.
Reiter RA; Knöbl P; Varadi K; Turecek PL
Blood; 2003 Feb; 101(3):946-8. PubMed ID: 12393734
[TBL] [Abstract][Full Text] [Related]
6. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
Frank RD; Kunz D; Wirtz DC
Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
[TBL] [Abstract][Full Text] [Related]
7. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation.
Park YD; Yoshioka A; Kawa K; Ishizashi H; Yagi H; Yamamoto Y; Matsumoto M; Fujimura Y
Bone Marrow Transplant; 2002 May; 29(9):789-94. PubMed ID: 12040478
[TBL] [Abstract][Full Text] [Related]
8. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
[TBL] [Abstract][Full Text] [Related]
9. Acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance.
Yujiri T; Nakamura Y; Oota I; Nakano K; Tanizawa Y
Ann Hematol; 2014 Aug; 93(8):1427-8. PubMed ID: 24337448
[No Abstract] [Full Text] [Related]
10. Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias.
Dicke C; Schneppenheim S; Holstein K; Spath B; Bokemeyer C; Dittmer R; Budde U; Langer F
Ann Hematol; 2016 May; 95(6):945-57. PubMed ID: 27040683
[TBL] [Abstract][Full Text] [Related]
11. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):577-88. PubMed ID: 16977568
[TBL] [Abstract][Full Text] [Related]
12. Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease.
Dane KE; Lindsley JP; Kickler T; Streiff MB; Moliterno A; Yui J; Naik R; Chaturvedi S
Blood Adv; 2021 Jul; 5(14):2813-2816. PubMed ID: 34269797
[TBL] [Abstract][Full Text] [Related]
13. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.
van Genderen PJ; Vink T; Michiels JJ; van 't Veer MB; Sixma JJ; van Vliet HH
Blood; 1994 Nov; 84(10):3378-84. PubMed ID: 7949092
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and immediate treatment of acquired von Willebrand syndrome revealed by recurrent cerebral hemorrhage.
Pineau-Vincent F; Legout A; Besancon-Bergelin A; Alani M; Laribi K; Lemaire P
Transfus Clin Biol; 2019 Nov; 26(4):356-358. PubMed ID: 31262628
[TBL] [Abstract][Full Text] [Related]
15. Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy.
Green A; Shen YP; Nelson AT; Sarode R; Ibrahim IF; Cao J; Afraz S; Yates SG
Ann Hematol; 2022 Dec; 101(12):2627-2631. PubMed ID: 36194257
[TBL] [Abstract][Full Text] [Related]
16. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP
Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386
[TBL] [Abstract][Full Text] [Related]
17. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
[TBL] [Abstract][Full Text] [Related]
18. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.
Federici AB
Hum Immunol; 2005 Apr; 66(4):422-30. PubMed ID: 15866707
[TBL] [Abstract][Full Text] [Related]
19. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
20. [Acquired von Willebrand syndrome].
de Lange DW; Fijnheer R; Wittebol S
Ned Tijdschr Geneeskd; 2003 Sep; 147(37):1808-11. PubMed ID: 14526622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
